According to a new report by Polaris Market Research, the global GLP-1 market was valued at USD 52.82 billion in 2025 and is projected to reach USD 133.92 billion by 2034, expanding at a CAGR of 10.9% over the forecast period. Growth is underpinned by rising type 2 diabetes prevalence, expanding demand for obesity treatment, and accelerating adoption of oral and long-acting drug formulations across key end-use markets.

The GLP-1 market size is attracting strong attention as these therapies move beyond diabetes management and become increasingly associated with weight management and metabolic health. Growing consumer awareness, expanding treatment options, and continued pharmaceutical investment are creating new opportunities. The rising demand for GLP-1 weight loss treatments is also encouraging companies to explore new formulations and delivery methods, keeping this market firmly in the spotlight.

What Is Driving GLP-1 Market Growth?

Demand is climbing as the global burden of type 2 diabetes converges with a rapid rise in obesity and related metabolic disorders. Manufacturers and healthcare providers are prioritizing convenient, patient-friendly treatment formats, pushing GLP-1 adoption across therapeutic and geographic segments. Polaris analysts note that expanding regulatory approvals for obesity indications position the category for sustained double-digit growth through 2034, with the obesity segment emerging as the largest revenue contributor and oral GLP-1 therapies posting the fastest incremental gains.

Key Trends Shaping the GLP-1 Industry

Long-Acting and Oral Formulation Innovation

Manufacturers are prioritizing longer-acting molecules that require less frequent dosing, alongside oral GLP-1 formulations that eliminate the need for injections, improving patient compliance and driving broader technology advancement and product innovation across the category.

Expanding Regulatory and Clinical Guidance

Bodies such as the American Diabetes Association and the European Association for the Study of Diabetes continue to widen clinical recommendations for GLP-1 use, reinforcing the regulatory landscape that supports uptake across diabetes, obesity, and cardiometabolic risk populations.

Strategic Partnerships and Pipeline Expansion

Collaborations between pharmaceutical companies and wellness or behavioral-health platforms, together with a deep late-stage pipeline of dual and triple agonists, are reshaping the competitive landscape and market outlook for next-generation GLP-1 therapies.

Explore The Complete Comprehensive Report Here:

https://www.polarismarketresearch.com/industry-analysis/glp-1-market 

Market Segmentation: Breaking Down the Market

Polaris segments the GLP-1 market by type of GLP-1 agonist drug, route of administration, target indication, type of molecule, and region, giving each buyer persona a citable, standalone data point.

By Type of GLP-1 Agonist Drugs

The long-acting GLP-1 agonist segment led the market in 2025, supported by superior dosing convenience, improved patient adherence, and sustained therapeutic efficacy relative to short-acting alternatives.

By Route of Administration

Parenteral formulations held the larger share of revenue in 2025, but the oral segment is projected to expand at the fastest pace through 2034 as noninvasive, patient-friendly treatment options gain traction in primary care settings.

By Target Indication

The obesity segment held the largest market share in 2025, propelled by growing clinical acceptance and expanding regulatory approvals, while type 2 diabetes remains the foundational indication supporting the broader base of demand.

By Type of Molecule

Biologics are expected to post substantial growth through the forecast period given their strong clinical performance, precise targeting, and extended half-life compared with small-molecule alternatives.

Regional Outlook: Where Is GLP-1 Growing Fastest?

North America led the market in 2025 on the back of high disease prevalence, established reimbursement frameworks, and early adoption of novel therapies, with the United States remaining the largest single market. Asia Pacific is projected to post the fastest CAGR through 2034, driven by rising diabetes and obesity case counts in China and India alongside expanding healthcare access. Europe rounds out the top three, supported by structured disease-management programs and strong clinical research infrastructure.

Competitive Landscape: Leading GLP-1 Companies

Key players profiled in the report include Novo Nordisk, Eli Lilly, AstraZeneca, Pfizer, Roche, Sanofi, Boehringer Ingelheim, Hanmi Pharmaceutical, D&D Pharmatech, and Tonghua Dongbao Pharmaceutical, who are focusing on late-stage pipeline development and strategic partnerships to strengthen market position across the obesity and type 2 diabetes segments outlined above. Recent moves include expanded manufacturing capacity to address ongoing supply constraints and new oral-formulation programs aimed at deepening share in North America and Asia Pacific.

Why It Matters for Buyers Evaluating the GLP-1 Market

For stakeholders researching the GLP-1 market, this report benchmarks market share, segment-level pricing, and forecast data — by drug type, route of administration, target indication, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking oral GLP-1 therapies as a growth adjacency.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

Hydrogen Hubs Market

Dry Van Container Market

Secure Access Service Edge Market

Vaccine Adjuvants Market

Chainsaw Market

Chainsaw Market

Guns and Accessories Market

Hematologic Malignancies Therapeutics Market

Enteric Empty Capsules Market